Research and laboratory use only. Not for human consumption.
TB-500
TB-500 is commonly used to describe a synthetic peptide corresponding to the actin-binding region of thymosin beta-4. It is primarily associated with experimental research into cellular migration, angiogenesis and tissue-repair biology.
What is TB-500?
TB-500 is a synthetic peptide commonly identified as an acetylated seven-amino-acid fragment of thymosin beta-4 (Tβ4), corresponding to residues 17–23 of the parent peptide.
Its sequence is generally represented as Ac-LKKTETQ-OH. The central LKKTET motif is important because this region of thymosin beta-4 is associated with actin binding and several biological processes involving cytoskeletal organisation and cell migration.
Scientific interest surrounding TB-500 therefore originates largely from the much broader research literature surrounding thymosin beta-4.
This creates an important evidence problem: TB-500 and full-length thymosin beta-4 are often discussed interchangeably online even though they are not the same molecule.
Why is it called TB-500?
The TB designation reflects the compound's relationship to thymosin beta-4, often abbreviated Tβ4 or TB4.
The term TB-500 is widely used for a synthetic research peptide based on a biologically important region of the parent thymosin beta-4 molecule.
The “500” should not be interpreted as meaning that the peptide contains 500 amino acids or has a molecular weight of 500. It functions as part of the compound's research designation.
TB-500 is not the same molecule as thymosin beta-4
This distinction is essential when interpreting the scientific literature. Much of the research frequently attributed to TB-500 actually investigated full-length thymosin beta-4.
Synthetic Fragment
Commonly identified as an acetylated seven-residue peptide corresponding to residues 17–23 of thymosin beta-4.
This is the compound discussed on this ASA Research profile.
Thymosin Beta-4
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide found in mammalian tissues. It has an extensive biological research history.
Full-length Tβ4 has undergone human clinical investigation in areas including ophthalmology, wound repair and other therapeutic research.
Results from those studies cannot automatically be treated as evidence for TB-500.
A clinical trial using full-length thymosin beta-4 does not establish the safety or efficacy of the shorter TB-500 fragment. ASA Research separates evidence for the two molecules throughout this profile.
Amino-acid sequence
The commonly identified TB-500 fragment contains seven amino-acid residues derived from the central region of thymosin beta-4.
Why are researchers interested in TB-500?
Interest in TB-500 originates primarily from the biology of thymosin beta-4 and its actin-binding region. Several processes associated with tissue repair have therefore become areas of experimental investigation.
Musculoskeletal Biology
Thymosin beta-4 research has examined muscle, tendon and ligament injury models, contributing to interest in its active fragments.
Angiogenesis
The LKKTETQ region has been investigated in connection with endothelial migration and formation of new blood vessels.
Cell Migration
Actin regulation is fundamental to cellular movement, making cytoskeletal dynamics a central area of thymosin beta-4 research.
Wound Repair
Full-length thymosin beta-4 has been extensively investigated in experimental skin, corneal and wound-healing models.
How might the thymosin beta-4 pathway influence tissue biology?
Much of the mechanistic rationale surrounding TB-500 is derived from studies of thymosin beta-4 and the biological activity of its LKKTET-containing region. These mechanisms should not be interpreted as proven human effects of TB-500.
Actin Interaction
The LKKTET region forms part of the important actin-binding domain of thymosin beta-4, linking the molecule to cytoskeletal dynamics.
Cellular Migration
Regulation of the actin cytoskeleton can influence the movement of cells involved in tissue repair.
Angiogenic Signalling
Experimental research has associated thymosin beta-4 and its active region with endothelial migration and angiogenesis.
Repair Signalling
Thymosin beta-4 research has implicated multiple intracellular pathways involved in survival, migration and tissue remodelling.
What might this research eventually contribute to?
The biological findings surrounding thymosin beta-4 and its active domains have generated interest in several possible therapeutic research areas. These are research hypotheses rather than approved uses for TB-500.
Muscle Injury & Repair
Experimental thymosin beta-4 research has examined skeletal-muscle regeneration and cellular responses following injury. Whether the TB-500 fragment could produce clinically useful effects in humans remains unestablished.
Tendon & Ligament Research
Preclinical work involving connective-tissue injury has contributed to interest in thymosin beta-4 pathways. There is no established human therapeutic indication for TB-500 in tendon or ligament injury.
Wound & Corneal Repair
Full-length thymosin beta-4 has progressed into human investigation for wound and ocular-surface applications. Those studies provide important information about Tβ4 biology but are not clinical evidence for the TB-500 fragment.
Cardiovascular Repair Biology
Experimental Tβ4 research has examined cellular survival, vascular responses and cardiac repair following injury. Translation into established human therapy remains an area of investigation.
Evidence obtained using full-length thymosin beta-4, isolated cells or animal models cannot establish that TB-500 is safe or effective for treating human injury or disease.
How strong is the evidence?
TB-500 requires an unusually careful evidence assessment because much of the research commonly associated with the compound was actually performed using full-length thymosin beta-4.
Mechanistic Evidence
The LKKTET region has biological relevance within thymosin beta-4, particularly in relation to actin and cellular migration.
Preclinical Tβ4 Evidence
A substantial laboratory and animal literature exists for full-length thymosin beta-4 across multiple tissue systems.
TB-500 Human Evidence
Direct controlled human evidence for the seven-residue TB-500 fragment is extremely limited or absent.
Established Medicine
TB-500 has not reached this stage and has no established approved therapeutic indication.
Has TB-500 been studied in humans?
Human studies of full-length thymosin beta-4 should not be confused with clinical evidence for the shorter TB-500 fragment.
The human clinical literature most frequently associated with “TB-500” primarily concerns full-length thymosin beta-4, rather than the seven-amino-acid TB-500 fragment.
Full-length Tβ4 has undergone human investigation in several areas, including wound healing, ophthalmology and systemic administration. Ophthalmic formulations have progressed into later-stage clinical development.
These studies are scientifically relevant because TB-500 originates from an active region of Tβ4, but they cannot demonstrate the safety, appropriate exposure, pharmacokinetics or efficacy of TB-500 itself.
There is currently no established clinical evidence demonstrating that TB-500 improves muscle, tendon or ligament healing in humans.
Where is TB-500 in the development process?
The TB-500 fragment remains an investigational research compound. Its parent molecule, thymosin beta-4, has progressed considerably further into clinical research, but that development should not be attributed directly to TB-500.
Investigational peptide fragment
TB-500 has not been established as an approved therapeutic medicine. Direct human evidence for the fragment remains substantially behind the clinical research performed with full-length thymosin beta-4.
What don't we know yet?
Factors affecting peptide stability
Stability depends on the exact peptide identity, formulation, physical form and analytical specification. Researchers should rely on compound-specific analytical documentation rather than assuming that stability data for full-length thymosin beta-4 applies to TB-500.
Temperature
Temperature can influence peptide degradation and long-term chemical stability.
Light
Light exposure may contribute to degradation of susceptible research materials.
Moisture
Moisture can affect physical and chemical stability of peptide preparations.
Solution Conditions
pH, solvent, buffer composition and concentration can affect stability in experimental solutions.
Investigational — not an approved medicine
TB-500 remains an investigational research compound. It does not have an established approved therapeutic indication, and reliable human safety and efficacy have not been demonstrated for the TB-500 fragment.
ASA Research Labs provides this information for scientific and educational purposes only. Nothing on this page should be interpreted as medical advice, dosing guidance or a recommendation for human use.
Selected scientific references
These publications provide background on thymosin beta-4 biology, its actin-binding region, tissue-repair research and clinical development. Where a study concerns full-length Tβ4 rather than TB-500, this distinction should be retained when interpreting its findings.
Scientific research information only
This profile is provided for scientific and educational information. TB-500 is an investigational compound and is not presented by ASA Research Labs as an approved medicine or treatment. Discussion of thymosin beta-4, laboratory experiments, animal studies, potential applications or clinical research does not establish the safety or efficacy of TB-500. This information is not medical advice and does not provide instructions for administration, dosing or human use.